Prothena to Participate in Upcoming Healthcare Conferences
Prothena plc (NASDAQ:PRTA), a late-stage clinical biotech company, has announced its participation in two upcoming healthcare conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, where it will hold one-on-one investor meetings. Additionally, Prothena will participate in the Cantor Global Healthcare Conference on September 17, featuring a fireside chat at 1:55 PM ET.
Investors can access a live webcast of the fireside chat through Prothena's website. A replay will be available for 90 days following the presentation. This engagement in high-profile conferences highlights Prothena's commitment to investor relations and showcases its robust pipeline of investigational therapeutics focused on protein dysregulation.
Prothena plc (NASDAQ:PRTA), un'azienda biotecnologica in fase avanzata, ha annunciato la sua partecipazione a due prossimi conferenze nel settore sanitario. L'azienda parteciperà al 22° Congresso Annuale Globale sulla Sanità di Morgan Stanley il 5 settembre, dove terrà incontri individuali con gli investitori. Inoltre, Prothena prenderà parte al Congresso Globale sulla Sanità di Cantor il 17 settembre, con un'intervista informale alle 13:55 ET.
Gli investitori possono accedere a una trasmissione in diretta dell'intervista informale attraverso il sito web di Prothena. Una registrazione sarà disponibile per 90 giorni dopo la presentazione. Questa partecipazione a conferenze di alto profilo sottolinea l'impegno di Prothena nei rapporti con gli investitori e mette in evidenza il suo robusto portafoglio di terapie in fase di sperimentazione focalizzate sulla disfunzione delle proteine.
Prothena plc (NASDAQ:PRTA), una empresa biotecnológica en fase avanzada, ha anunciado su participación en dos próximas conferencias de atención médica. La compañía asistirá a la 22ª Conferencia Anual Global de Salud de Morgan Stanley el 5 de septiembre, donde realizará reuniones individuales con inversores. Además, Prothena participará en la Conferencia Global de Salud de Cantor el 17 de septiembre, con un chat al aterdecer a la 1:55 PM ET.
Los inversores podrán acceder a una transmisión en vivo del chat a través del sitio web de Prothena. Habrá una repetición disponible durante 90 días después de la presentación. Esta participación en conferencias de alto perfil resalta el compromiso de Prothena con las relaciones con los inversores y muestra su sólido portafolio de terapias en investigación centradas en la disfunción proteica.
Prothena plc (NASDAQ:PRTA)는 후기 단계의 임상 생명공학 회사로 두 개의 다가오는 의료 회의에 참석할 계획을 발표했습니다. 회사는 9월 5일에 모건 스탠리 제22회 연례 글로벌 의료 회의에 참석하여 개별 투자자 회의를 진행할 예정입니다. 추가로, Prothena는 9월 17일에 칸토 글로벌 의료 회의에 참여하여 오후 1시 55분 ET에 대담을 진행합니다.
투자자들은 Prothena 웹사이트를 통해 대담의 생중계를 볼 수 있습니다. 발표 후 90일 동안 다시 볼 수 있습니다. 이러한 고프로필 회의 참여는 Prothena의 투자자 관계에 대한 의지를 강조하며, 단백질 조절 이상에 초점을 맞춘 연구 중인 치료제 파이프라인을 보여줍니다.
Prothena plc (NASDAQ:PRTA), une entreprise biopharmaceutique en phase avancée, a annoncé sa participation à deux prochaines conférences sur la santé. L'entreprise assistera à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 5 septembre, où elle tiendra des réunions individuelles avec des investisseurs. De plus, Prothena participera à la Conférence Mondiale sur la Santé de Cantor le 17 septembre, avec un chat au coin du feu à 13h55 ET.
Les investisseurs peuvent accéder à un webinaire en direct du chat au coin du feu via le site web de Prothena. Un enregistrement sera disponible pendant 90 jours après la présentation. Cet engagement dans des conférences de haut niveau souligne l'engagement de Prothena envers les relations avec les investisseurs et met en avant son solide pipeline de thérapies en recherche axées sur la dysrégulation des protéines.
Prothena plc (NASDAQ:PRTA), ein Biotechnologieunternehmen in der späten klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Gesundheitskonferenzen angekündigt. Das Unternehmen wird am 5. September an der 22. Jahreskonferenz für globale Gesundheit von Morgan Stanley teilnehmen, bei der Einzelgespräche mit Investoren stattfinden werden. Darüber hinaus wird Prothena am 17. September an der Cantor Global Healthcare Conference teilnehmen, mit einem Gespräch am Kamin um 13:55 Uhr ET.
Investoren können das Live-Webcast des Gesprächs über die Website von Prothena verfolgen. Eine Wiederholung wird 90 Tage nach der Präsentation verfügbar sein. Dieses Engagement auf hochkarätigen Konferenzen hebt Prothena's Engagement für Investor Relations hervor und zeigt seine umfangreiche Pipeline von experimentellen Therapeutika, die sich auf Protein-Dysregulation konzentrieren.
- None.
- None.
- Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5; 1x1 investor meetings will be held
- Cantor Global Healthcare Conference on Tuesday, September 17; a fireside chat will be held at 1:55 PM ET
A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829150219/en/
Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Source: Prothena Corporation plc
FAQ
What conferences will Prothena (PRTA) attend in September 2023?
When is Prothena's (PRTA) fireside chat at the Cantor Global Healthcare Conference?
How can investors access Prothena's (PRTA) fireside chat webcast?
How long will the replay of Prothena's (PRTA) conference presentation be available?
